These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18667303)

  • 1. Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy.
    Uchida M; Okazaki K; Mukaiyama H; Isawa H; Kobayashi H; Shiohara H; Muranaka H; Kai Y; Kikuchi N; Takeuchi H; Yokoyama K; Tsuji E; Ozawa T; Hoyano Y; Koizumi T; Misawa K; Hara K; Nakano S; Murakami Y; Okuno H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4682-7. PubMed ID: 18667303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
    Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
    Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
    Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
    Weller T; Alig L; Beresini M; Blackburn B; Bunting S; Hadváry P; Müller MH; Knopp D; Levet-Trafit B; Lipari MT; Modi NB; Müller M; Refino CJ; Schmitt M; Schönholzer P; Weiss S; Steiner B
    J Med Chem; 1996 Aug; 39(16):3139-47. PubMed ID: 8759635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa.
    Maryanoff BE; McComsey DF; Costanzo MJ; Yabut SC; Lu T; Player MR; Giardino EC; Damiano BP
    Chem Biol Drug Des; 2006 Jul; 68(1):29-36. PubMed ID: 16923023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR
    J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-substituted bis-C-alkyloxadiazolones as dual effectors: efficient intermediates to amidoximes or amidines and prodrug candidates of potent antimalarials.
    Degardin M; Wein S; Durand T; Escale R; Vial H; Vo-Hoang Y
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5233-6. PubMed ID: 19643611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of amidoxime derivatives for orally potent C-alkylamidine-based antimalarial agents.
    Ouattara M; Wein S; Denoyelle S; Ortial S; Durand T; Escale R; Vial H; Vo-Hoang Y
    Bioorg Med Chem Lett; 2009 Feb; 19(3):624-6. PubMed ID: 19124242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.
    Riggs JR; Kolesnikov A; Hendrix J; Young WB; Shrader WD; Vijaykumar D; Stephens R; Liu L; Pan L; Mordenti J; Green MJ; Sukbuntherng J
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2224-8. PubMed ID: 16458507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of factor Xa inhibitors and their prodrugs.
    Song Y; Clizbe L; Bhakta C; Teng W; Wong P; Huang B; Tran K; Sinha U; Park G; Reed A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Jan; 13(2):297-300. PubMed ID: 12482444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin.
    Katakura S; Nagahara T; Hara T; Iwamoto M
    Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
    Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
    J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.
    Schweinitz A; Dönnecke D; Ludwig A; Steinmetzer P; Schulze A; Kotthaus J; Wein S; Clement B; Steinmetzer T
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1960-5. PubMed ID: 19250826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.
    Zhang P; Bao L; Zuckett JF; Jia ZJ; Woolfrey J; Arfsten A; Edwards S; Sinha U; Hutchaleelaha A; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Feb; 14(4):989-93. PubMed ID: 15013007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
    Choi-Sledeski YM; McGarry DG; Green DM; Mason HJ; Becker MR; Davis RS; Ewing WR; Dankulich WP; Manetta VE; Morris RL; Spada AP; Cheney DL; Brown KD; Colussi DJ; Chu V; Heran CL; Morgan SR; Bentley RG; Leadley RJ; Maignan S; Guilloteau JP; Dunwiddie CT; Pauls HW
    J Med Chem; 1999 Sep; 42(18):3572-87. PubMed ID: 10479289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors.
    Imaeda Y; Kuroita T; Sakamoto H; Kawamoto T; Tobisu M; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
    J Med Chem; 2008 Jun; 51(12):3422-36. PubMed ID: 18507371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production.
    Miyazaki H; Ogiku T; Sai H; Ohmizu H; Murakami J; Ohtani A
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6419-22. PubMed ID: 18993062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors.
    Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Isobe Y; Furugohri T; Kanno H
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4683-8. PubMed ID: 17555959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.
    Choi-Sledeski YM; Kearney R; Poli G; Pauls H; Gardner C; Gong Y; Becker M; Davis R; Spada A; Liang G; Chu V; Brown K; Collussi D; Leadley R; Rebello S; Moxey P; Morgan S; Bentley R; Kasiewski C; Maignan S; Guilloteau JP; Mikol V
    J Med Chem; 2003 Feb; 46(5):681-4. PubMed ID: 12593648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
    J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.